Skip to main content

Biosurfactant from vaginal Lactobacillus crispatus BC1 as a promising agent to interfere with Candida adhesion



Lactobacillus spp. dominating the vaginal microbiota of healthy women contribute to the prevention of urogenital and sexually transmitted infections. Their protective role in the vagina can be mediated by Lactobacillus cells themselves, metabolites or bacterial components, able to interfere with pathogen adhesion and infectivity. Vulvovaginal candidiasis (VVC) is a common genital infection, caused by the overgrowth of opportunistic Candida spp. including C. albicans, C. glabrata, C. krusei and C. tropicalis. Azole antifungal drugs are not always efficient in resolving VVC and preventing recurrent infections, thus alternative anti-Candida agents based on vaginal probiotics have gained more importance. The present work aims to chemically characterize the biosurfactant (BS) isolated from a vaginal Lactobacillus crispatus strain, L. crispatus BC1, and to investigate its safety and antiadhesive/antimicrobial activity against Candida spp., employing in vitro and in vivo assays.


BS isolated from vaginal L. crispatus BC1 was characterised as non-homogeneous lipopeptide molecules with a critical micellar concentration value of 2 mg/mL, and good emulsification and mucoadhesive properties. At 1.25 mg/mL, the BS was not cytotoxic and reduced Candida strains’ ability to adhere to human cervical epithelial cells, mainly by exclusion mechanism. Moreover, intravaginal ( inoculation of BS in a murine experimental model was safe and did not perturb vaginal cytology, histology and cultivable vaginal microbiota. In the case of challenge of mice with C. albicans, BS was able to reduce leukocyte influx.


These results indicate that BS from vaginal L. crispatus BC1 is able to interfere with Candida adhesion in vitro and in vivo, and suggest its potential as a preventive agent to reduce mucosal damage occasioned by Candida during VVC.


Candida species are part of the mucosal microbiota of the gastrointestinal and genitourinary tracts of most healthy women. In certain conditions, these yeasts can become opportunistic pathogens and overgrow on the vulvovaginal mucosa, originating symptomatic vulvovaginal candidiasis (VVC). Until some years ago, the species most commonly detected in VVC was C. albicans. However, during the last two decades, with the development of more accurate molecular diagnostics, infections by different species (i.e. C. glabrata, C. krusei and C. tropicalis) have emerged producing an increase in causative species of VVC [1]. Antifungal azoles are usually applied for VVC treatment; however, the prolonged exposition to these drugs can generate high resistance pressure, thus promoting the appearance of azole-resistant Candida strains. Thus, the search for anti-Candida agents with new pharmacological targets is a priority for effective prevention and treatment of these types of infections [2].

Lactobacilli are the predominant microorganisms in the vaginal microbiota of healthy women that contribute to preventing urogenital and sexually transmitted infections [3,4,5]. The protective role in the vagina is exerted through different mechanisms including: adhesion and permanence on the epithelium (promoted by biofilm formation), competitive exclusion against pathogens, production of antimicrobial compounds and/or modulation of the host’s immune response [3, 6,7,8,9]. In this scenario, probiotics or pharmaceuticals containing lactobacilli or their derivatives represent a novel strategy to reconstitute the vaginal microbiota and prevent/treat urogenital infections [10, 11]. The World Health Organization defines probiotics as “live microorganisms which, when administered in adequate amounts, confer a health benefit on the host” [12, 13]. Pharmabiotics include “live or dead microorganisms, as well as microbial components and metabolites that can interact beneficially with the host” [14].

Different scientists have shown that specific cell surface components of lactobacilli and some metabolites contribute to their beneficial effects [15,16,17,18,19]. Biosurfactants (BS) are amphiphilic compounds produced by microorganisms, anchored on the surface or secreted to the outside, with outstanding surface and emulsifying properties [20]. These molecules, mainly secondary metabolites, exert critical functions in the survival of producer microorganisms by facilitating the transport of nutrients, interfering with microorganism–host interactions and “quorum sensing”, or acting as antimicrobial, anti-adhesive and anti-biofilms agents [15, 16, 21, 22]. Differently from synthetic surfactants, BS are considered “green” compounds because of their natural origin, biodegradability and low toxicity [23], which support their use in medicine. Among pharmaceutical applications, BS antibacterial, antiviral, antifungal and anticancer effects have been reported [21, 24, 25]. Recently, two studies have been focused on the formulation of BS, isolated from a vaginal L. gasseri strain, inside liposomes active against Candida and methicillin resistant Staphylococcus aureus strains [26, 27].

In the perspective to contribute to the understanding of the biological role of lactobacilli in the vaginal niche as well as to promote the application of their isolated components, the present work aims to chemically characterize the BS isolated from a vaginal Lactobacillus crispatus strain, and to investigate its cytotoxicity and antiadhesive activity against Candida spp., employing in vitro and in vivo assays.


Microorganisms and culture conditions

Lactobacillus crispatus BC1, originally isolated from the vaginal swab of a healthy premenopausal volunteer following the protocol approved by the Ethics Committee of the University of Bologna (52/2014/U/Tess) and selected for its antimicrobial properties [28], was used in this study. The strain was cultured in de Man, Rogosa and Sharpe (MRS) (Beckton, Dickinson and Co., Milan, Italy) broth supplemented with 0.05% l-cysteine (Sigma-Aldrich, Milan, Italy), at 37 °C for 24 h in anaerobic jars containing GasPak EZ (Beckton, Dickinson and Co.).

Six clinical isolates of Candida spp. (C. albicans 1, C. albicans 2, C. albicans 4, C. tropicalis, C. krusei and C. glabrata), belonging to a collection of yeasts isolated from vaginal swabs of premenopausal, VVC affected-women during routine diagnostic procedures at the Microbiology Laboratory of Sant’Orsola-Malpighi University Hospital of Bologna, were used in the present study [28]. Candida strains were grown aerobically at 35 °C for 16 h in Sabouraud dextrose agar (Beckton, Dickinson and Co.).

Isolation of BS from L. crispatus BC1

The cell-bound BS was isolated according to the method previously published by Abruzzo et al. [26]. Briefly, 100 mL of an overnight culture of L. crispatus BC1 were inoculated in 900 mL of MRS broth and allowed to grow for 24 h in anaerobic jars containing GasPak EZ. Then, the cell pellet was harvested by centrifugation (10.000×g, 10 min), washed twice in sterile water, before being re-suspended in 300 mL of sterile PBS (2.38 g/L Na2HPO4, 0.19 g/L KH2PO4 and 8 g/L NaCl) and gently stirred at room temperature for 2 h to release the cell-bound BS. Subsequently the suspension was centrifuged and the supernatant filtered through a 0.22 μm pore size filter (PES 0.22 μm syringe filters, VWR International, Milan, Italy). Cell-free supernatant was then subjected to dialysis against demineralized water in a Cellu-Sep© membrane (molecular weight cut-off 6000–8000 Da; Spectra/Por 2 dialysis membrane, Spectrum Laboratories Inc., Rancho Dominguez, CA) for 24 h at room temperature, and freeze-dried at 0.01 atm and − 45 °C (Christ Freeze Dryer ALPHA 1–2, Milan, Italy). This procedure allowed to obtain about 60 mg of lyophilized BS crude multi-component product (defined as BS) from 1 L of L. crispatus BC1 culture.

Chemical characterization of BS

Fourier transformed infrared spectroscopy (FT-IR)

Fourier transformed infrared spectroscopy analyses were conducted with a Jasco FT-IR 4100 spectrophotometer (Jasco, Lecco, Italy) in order to determine the functional groups of the isolated BS. Freeze-dried BS was gently triturated with KBr powder (Sigma-Aldrich) with BS/KBr weight ratio 1:10 and then pressed using a hydraulic press at a pressure of 100 tons for 5 min. The disc was placed in the sample holder and scanned between 4000 and 450 cm−1.

Mass spectrometric analysis

BS characterisation by mass spectrometry (MS) assays was carried out according to the previously published method by Abruzzo et al. [26], by means of a Waters (Milford, MA, USA) Micromass Quattro Micro triple quadrupole (QqQ) mass spectrometer interfaced with an electrospray ion source operating in positive and negative ionisation modes (ESI+/ESI−). BS was dissolved in ultrapure water and diluted with the same solvent to reach the concentration of 10 μg/mL. BS solutions were directly infused by means of a Harvard Apparatus (Holliston, MA) 11 Plus programmable syringe pump into the ESI source, at a flowrate of 10 μL/min. Data processing was performed using Waters MassLynx 4.1 software. Full scan MS spectra (scan duration: 500 ms) were acquired by applying MS parameters as follows: capillary voltage was set at 3.0 kV, while cone voltage was tested within a range of 15–100 V in order to test variation in BS ionisability and possible fragmentation patterns; source and desolvation temperatures were kept at 120 °C and 150 °C, respectively; cone gas (N2) flow was set to 50 L/h while desolvation gas (N2) flow was 200 L/h.

Surface-activity determination and critical micelle concentration of BS

The critical micellar concentration (CMC) of BS was measured by the ring method using a tensiometer (K8600E Krüss GmbH, Hamburg, Germany) equipped with a 1.9 cm platinum ring [26]. Surface tension (dyne/cm) of BS aqueous solutions at different concentrations (0.03–8.0 mg/mL) was measured at room temperature. The concentration at which surfactant molecules aggregate and form micelles in aqueous environment (CMC) was determined by plotting the surface tension as a function of the logarithm of BS concentration. CMC is represented as the point at which the baseline of minimal surface tension intersects the slope where surface tension shows a linear decline.

To evaluate BS stability in a pH range representative of the human vaginal environment in physiological and pathological conditions [4], BS was dissolved (1.25 mg/mL) in aqueous solutions adjusted to pH 3, 4, 5 and 6 with 0.1 M HCl, and the surface tension was determined as described above.

Emulsification properties of BS

For this study, 1 mL of BS solution (1.25 mg/mL), 4 mL of water and 6 mL of olive oil, sunflower oil or wheat germ oil (Polichimica, Bologna, Italy) were vigorously shaken in graduated glass test tubes for 2 min to obtain maximum emulsification [29]. After 24 h, the height of the emulsion was measured and emulsification index (EI24) was calculated using the following equation:

$$ {\text{EI24}}\left( \% \right) = {\text{Height of emulsion layer}} \times 100/{\text{Total height}} . $$

Water and Tween 80 (Fluka, Milan, Italy) at a concentration of 1 mg/mL were used as negative and positive controls, respectively.

Mucoadhesive properties

Mucoadhesive properties were determined through turbidimetric analysis of a suspension containing mucin and BS [30]. Mucin (Type II: crude, from porcine stomach, Sigma-Aldrich) was dispersed in water (0.08% w/v) and after 24 h the dispersion was centrifuged at 7500 rpm (GS-15R Centrifuge, Beckman Coulter, Milan, Italy) for 20 min in order to discharge the excess of mucin. Subsequently, the isolated mucin supernatant and a BS solution (1.25 mg/mL) were mixed (1:3 v/v) for 3 h. The turbidity of the mixture was measured at 650 nm (UV–Visible Spectrophotometer, Shimadzu Corporation, Australia) and compared to the controls (mucin supernatant and BS solution without mucin).

Cytotoxicity of BS on human cervical cells (HeLa)

The impact of BS on the proliferation of HeLa cells was evaluated by colorimetric assay with 3-(45-dimethylthiazol-2-yl)-2,5-diphenyltetrazol (MTT) [31]. HeLa cells were maintained in Dulbecco’s minimal essential medium (DMEM, Sigma-Aldrich), supplemented with 10% fetal bovine serum (Sigma-Aldrich) and 1% l-glutamine (Sigma-Aldrich). Cells were seeded at 10.000 cells/well in 96-well plates and grown to 70% confluence in 5% CO2 at 37 °C, in a NU4500E Water-Jacketed CO2 Incubator (Nuaire, Plymouth, MN). Subsequently, HeLa cells were treated with different concentrations of BS (0.3–10 mg/mL) and incubated at 37 °C with 5% CO2 for 24 h. Untreated cells were used as control. After incubation, 110 μL MTT solution in DMEM (final concentration 0.5 mg/mL) was added to each well and the plates incubated for 4 h at 37 °C with 5% CO2. The formazan crystals formed were dissolved by the addition of isopropanol (Sigma-Aldrich). After 15 min, the coloured formazan derivative was quantified by optical density (OD) at 570 nm and the inhibition percent calculated as follows: cell viability (%) = [1 − (ODsample/ODcontrol)] × 100.

Anti-adhesive activity of BS against Candida spp. in HeLa cells

The influence of BS on the adhesion of C. albicans (strains 1, 2 and 4), C. tropicalis, C. krusei or C. glabrata to HeLa cells was determined according to Parolin et al. [28]. Briefly, HeLa cells were grown on sterile glass coverslips placed in 6-well culture plates, up to 70% confluence. Three mechanisms of action: competition, exclusion and displacement, were investigated. For the competition test, 1 mL of Candida suspension [1 × 108 colony forming units (CFU) C. albicans, C. krusei or C. glabrata; and 1 × 107 CFU C. tropicalis] plus different concentrations of BS (0.00125–1.25 mg/mL) were added to each well and incubated at 37 °C for 1 h. For the exclusion test, the cell monolayers were firstly incubated with 1 mL of BS solutions (0.00125–1.25 mg/mL) for 1 h, and then added with the Candida suspensions for 1 h. For the displacement test, the monolayers were incubated first with Candida suspensions for 1 h, and then with BS for an additional hour. Once the incubation was finished, the cells were washed with PBS, fixed with May–Grünwald and stained with Giemsa (Sigma-Aldrich). The results were determined by optical microscopy (1000×), quantifying the number of Candida bound to HeLa cell. Each adhesion test was performed in duplicate, in two independent experiments, evaluating the fungal number in 200 randomly chosen epithelial cells.

Murine experimental model


Female BALB/c mice of 2-month-old from the inbred colony of CERELA (Centro de Referencia para Lactobacilos) were employed. Animals were housed and fed ad libitum, and a pseudo-estrous condition was weekly induced as previously described [32]. The experiments were independently repeated two times, with at least five animals for each experimental group and sampling day. The Institutional Laboratory Animal Care and Use Committee of CERELA approved the experimental CRL-BIOT-FB-2019/1A protocol applied in this work.

Safety studies

Mice were randomly assigned to two experimental groups: (a) Control mice: intravaginally ( inoculated with 20 µL saline once per day for 14 days; (b) BS-inoculated mice: inoculated with 20 µL BS (1.25 mg/mL in saline) once per day for 14 days. The experimental groups, the inoculation sequence and the sampling days are showed in Fig. 1a.

Fig. 1

Murine experimental models. a Safety assessment of biosurfactant (BS) from L. crispatus BC1 in the murine vaginal tract. b Preventive, simultaneous and preventive–simultaneous effect of BS against C. albicans 2 infection. H: Subcutaneous injection of 0.02 mg β-Estradiol 17-valerate (↑). Arrow correspond to one intravaginal ( inoculation of: saline (S, ), BS [20 µL containing 1.25 mg/mL of BS ( )], or C. albicans 2 [20 µL containing 106 CFU (C.a., )] into BALB/c mice. Sd ( ): sampling day

Anti-Candida activity of BS

Candida albicans 2 strain was employed in the following experiments to assess anti-Candida activity of BS, and the fungal inoculum was prepared as previously described [33].

Mice were randomly assigned to five experimental groups: (a) BS, BS-treated mice: inoculated with 20 µL BS (1.25 mg/mL) once per day for 7 days, then inoculated with saline, and again inoculated with BS once per day for 7 days; (b) Control, Candida-challenged mice: inoculated with saline once per day for 7 days, then challenged with 20 µL containing 1 × 106 CFU Candida, and again inoculated with saline once per day for 7 days; (c) Preventive, BS + Candida-treated mice: inoculated with 20 µL BS (1.25 mg/mL) once per day for 7 days, then challenged with 1 × 106 CFU Candida, and inoculated with saline once per day for 7 days; (d) Simultaneous, Candida + BS-treated mice: inoculated with saline once per day for 7 days, then challenged with 1 × 106 CFU Candida, and inoculated with 20 µL BS (1.25 mg/mL) once per day for 7 days; and (e) Preventive–simultaneous, BS + Candida + BS-treated mice: inoculated with 20 µL BS (1.25 mg/mL) once per day for 7 days, then challenged with 1 × 106 CFU Candida, and again inoculated with BS once per day for 7 days.

The experimental groups, the inoculation sequence and the sampling days of the protocols applied are schematized in Fig. 1b.

Sampling and analytical procedures

Vaginal washings and tissues were obtained according to De Gregorio et al. [32]. Cytology of vaginal washing and histology of vaginal tissues were performed with May–Grünwald–Giemsa and Hematoxylin–Eosin stains, respectively, as previously described [32].

The cultivable bacterial numbers in vaginal washing were determined (only in mice from safety protocol) by the serial dilution method in the following selective agar plates: MRS agar pH 6.4 (Biokar, France), Bile Esculin agar (Britania, Buenos Aires, Argentina), Mannitol Salt Agar (MSA; Britania) and Mc Conkey agar (Britania), to quantify the viable lactic acid bacteria (LAB), enterococci, staphylococci and enterobacteria, respectively, from the murine vaginal microbiota. Fungi were not evaluated because previous studies showed that bacteria, but not fungi were isolated from the vaginal autochthonous microbiota of BALB/c mice [32,33,34].

In the different experimental protocols for anti-Candida activity the following evaluations were performed: (a) Candida viable cell numbers by serial dilution method in Sabouraud glucose agar plates containing 0.05 g/L chloramphenicol (Britania) [33]; and (b) average number of leukocytes in vaginal smears (stained with May–Grünwald–Giemsa) counting on optical microscopy in at least 5 fields at 400× magnification.

Statistical analysis

Student’s t test was applied to compare emulsification properties of BS and Tween 80. Analysis of variance (ANOVA) using a general linear model was applied to analyse the effect of different BS concentrations on: (a) HeLa cell viability, and (b) adhesion of Candida spp. to HeLa cells. For in vivo tests, ANOVA (general linear model) was also used to determine the effects of factors (experimental group and sampling day) on the number of viable Candida and the leukocyte number. Graphic evaluation of residual values of the significant ANOVAs (P < 0.05) showed a distribution close to normal. Then, a Tukey’s test of multiple comparisons was applied, establishing a P < 0.05 value to determine the significant differences between mean values, using Minitab statistical software (version 16).


Chemical characterization of BS from L. crispatus BC1

Fourier transformed infrared spectroscopy

BS isolated from L. crispatus BC1 was analysed by FT-IR spectroscopy and the obtained spectrum is reported in Fig. 2. The peak at 3449 cm−1 was attributed to the stretching of N–H bond [26]. The peaks around 2925 cm−1, 1462 cm−1 and 2855 cm−1 are related to CH3 and CH2 groups, demonstrating the presence of aliphatic chains [35]. The absorbance at 2300–2400 cm−1 may be due to C=N stretching, while the peak at 1635 cm−1, relative to CO–N groups, indicated the presence of peptidic groups in the molecule [36]. The peaks at 1564 cm−1 and at 1402 cm−1 represented the carbonyl group (C=O) of carboxylic acid and C=H stretch [37], respectively. Finally, the absorption band at 1089 cm−1 was assigned to O–C–O extend vibrations of carboxylic acids [36].

Fig. 2

FT-IR spectrum of biosurfactant isolated from L. crispatus BC1

Full scan ESI–MS analysis

BS isolated from L. crispatus BC1 strain was analysed by means of a triple quadrupole mass analyser operating in ESI+ and ESI− mode. MS full scan spectra were acquired in an m/z range between 20 and 2000 by direct infusion of BS solutions at the concentration of 10 µg/mL in H2O, as such and following a mild basic and acid hydrolysis. Pure H2O was chosen as solvent for analysis, since the freeze-dried isolated BS powder showed poor solubility in methanol, acetonitrile and mixtures thereof. Acidification of aqueous BS solutions with 0.1% formic acid also gave rise to precipitate formation. MS spectra obtained in negative ionisation mode showed the absence of significant signals within the considered m/z range under any of the tested conditions. This suggests the lack of acid functions, typical of glycolipids (mainly rhamnolipids) which usually give rise to signals attributed to negatively charged ions in the 200–700 m/z range. Full scan spectra acquired in ESI+ mode, on the other hand, showed significant signals of increasing intensity as the cone voltage was increased (likely due to increased desolvation/ionisation). From the acquired spectra, some predominant signals were highlighted and tentatively attributed to single-charge ions ([M+H]+, m/z 1397.8), multiple charge ions ([M+2H]2+, m/z 700.5) and sodium adducts ([M+Na]+, m/z 1419.6). Within the same m/z ranges, minor signals were observed with cluster distribution (spaced by multiples of m/z 14) and tentatively attributable to lipid-like portions, thus suggesting to be homologs possessing the same amino acids sequence, but different fatty acid carbon chains. After the hydrolysis of purified BS with HCl in methanol, fatty acid methyl esters were extracted by using ethyl acetate and then analysed. From the obtained full scan MS signals, the putative identity of the main fatty acids has been assigned to β-hydroxytridecanoic acid (3-OH-C13), β-hydroxytetradecanoic acid (3-OH-C14), β-hydroxypentadecanoic acid (3-OH-C15) and β-hydroxyhexadecanoic acid (3-OH-C16). Moreover, both by increasing cone voltage and by analysing BS solutions subjected to mild basic hydrolysis, ion signals could be observed in the 50–200 m/z range, compatibly with the progressive fragmentation of amino acid portions attributable to tyrosine, serine, proline, glycine and arginine.

Surface-activity determination and critical micelle concentration of BS

The surface-active properties of BS mainly depend on its CMC value and its ability to lower surface tension and to stabilize emulsions [38]. BS produced by L. crispatus BC1 had the ability to reduce the surface tension from 63.75 ± 2.48 to 49.57 ± 1.31 dyne/cm under the tested concentrations (Fig. 3). Specifically, the surface tension gradually decreased with the increase of BS concentration and no further decrease was observed beyond BS concentration 2.0 mg/mL. The CMC value, calculated by plotting the surface tension as a function of the logarithm of BS concentration, was equal to 2.0 mg/mL. Considering that the human vaginal pH ranges from less than 4 to greater than 5 [4], the surface tension was also measured at pH ranging from 3 to 6. No significant difference (P > 0.05) was observed between the surface tension values obtained in water (53.67 ± 0.58 dyne/cm) and in aqueous solutions at pH 3, 4 and 5 (data not shown). At pH 6.0, a slightly lower surface tension (50.67 ± 1.15 dyne/cm) with respect to the values obtained in water and at pH 3 or 4 (P < 0.05) was obtained. These results highlighted the maintenance of the surfactant properties over a pH range from 3 to 6 and suggested the effectiveness of BS for vaginal application.

Fig. 3

Surface tension versus biosurfactant (BS) concentration (mg/mL). Data are plotted as mean values of surface tension (dyne/cm) ± standard deviation (n = 3)

Emulsification properties of BS

The emulsification activity of BS was determined against olive oil, sunflower oil and wheat germ oil. The maximum emulsification activity of BS was 66.0 ± 1.4% for wheat germ oil, followed by sunflower oil and olive oil (Fig. 4). In all cases, EI24 was higher than 50% and only slightly lower (P > 0.05) than that obtained with Tween 80 (used as control).

Fig. 4

Emulsification properties of biosurfactant (BS) from L. crispatus BC1. Emulsification index at 24 h (EI24%) of BS and Tween 80 calculated on different substrates: olive oil, sunflower oil and wheat germ oil. Data are plotted as mean values of EI24% ± standard deviation (n = 3)

Mucoadhesive properties of BS

Mucoadhesive properties of BS were investigated by measuring the turbidity at 650 nm of the mixture BS/mucin, compared to the turbidity of BS solution and mucin supernatant. The mixture of BS and mucin was characterized by a higher turbidity with respect to the controls, as a consequence of the interaction between BS and mucin [26]. Specifically, after 3 h the percentage increase of the turbidity was equal to 122 ± 2%.

Cytotoxic effect of BS on HeLa cells

Before studying the potential of BS towards Candida adhesion on HeLa cells, we assessed if BS could interfere with cell viability in this cellular model. Thus, HeLa cells were treated with different concentrations of BS for 24 h, and then subjected to MTT reduction assay. Concentrations of BS below 2.5 mg/mL did not significantly reduce cell viability. For higher BS concentrations, a dose-dependent reduction (P < 0.01) was observed. In particular, BS at the concentration of 2.5 mg/mL reduced cell viability by 15.63%; 5 mg/mL by 22.52%; and 10 mg/mL decreased viability by 39.43% (Fig. 5).

Fig. 5

Viability of cervix epithelial cells (HeLa) in presence of biosurfactant (BS) from L. crispatus BC1. Data are plotted as average values of cell viability (%) ± standard error. Statistically significant differences in mean values of cell viability (%) are indicated by different letters (P < 0.05)

Anti-adhesive activity of BS against Candida spp

In order to evaluate the antagonist effect of BS against Candida, the influence of different concentrations of BS (0.00125–1.25 mg/mL) on the adhesion of C. albicans, C. tropicalis, C. krusei and C. glabrata to HeLa cells was investigated (Fig. 6) by using exclusion, competition and displacement assays. The BS concentrations were selected on the basis of the previous experiment, as they did not affect HeLa cell proliferation.

Fig. 6

Interference of biosurfactant (BS) from L. crispatus BC1 with Candida adhesion to HeLa cells. C. albicans 1, 2 and 4 (ac), C. tropicalis (d) C. krusei (e) and C. glabrata (f). Exclusion, competition and displacement mechanisms were studied. The results were expresses as percentages of adherent yeasts per HeLa cell and compared to adhesion without BS (control value), taken as 100%. Data are plotted as average values of number of Candida/HeLa cells (%) ± standard error. Statistically significant differences in mean values in each test (exclusion, competition, displacement) are indicated by different letters (P < 0.05)

The activity of BS against yeast adhesion to HeLa cells showed to be Candida strain-specific because different results were observed among strains of the same species (C. albicans) (Fig. 6a–c), and different species (C. tropicalis, C. krusei and C. glabrata) (Fig. 6d–f). At the lowest dose of BS (0.00125 mg/mL), for some Candida strains, an apparent not-significant enhancement of Candida adhesion was observed, probably attributable to experimental variability or to a slight substrate-like effect of BS. For higher concentrations of BS, an inhibitory activity was demonstrated, being BS more effective by exclusion mechanism than by competition and displacement mechanisms.

In the exclusion test, a significant reduction of at least 50% was evidenced in the adhesion of C. albicans, C. tropicalis and C. krusei strains to HeLa cells at BS concentration of 0.125 mg/mL (Fig. 6a–e). C. albicans 1 and 2 adhesion was reduced even with lower concentrations (0.0125 and 0.00125 mg/mL, respectively) (Fig. 6a, b).

When evaluating the competition mechanism, the adhesion of C. albicans 2 and 4 to HeLa cells was significantly reduced by at least 50% with 0.0125 and 0.125 mg/mL BS (Fig. 6b, c). This effect was also evidenced for C. albicans 1 with 0.125 mg/mL BS and for C. tropicalis and C. krusei with 1.25 mg/mL BS. For C. glabrata, adhesion was decreased with BS concentrations ranging from 0.0125 to 1.25 mg/mL; however, this reduction was not significant compared to control, demonstrating that C. glabrata is the most resistant strain/species (Fig. 6f).

In the displacement test, a significant reduction in the adhesion of C. tropicalis and C. krusei to HeLa cells was only evidenced in the presence of 0.125 and 1.25 mg/mL BS, respectively, compared to their controls. The BS was not able to interfere with the adhesion of the other tested Candida strains in the displacement protocols.

Studies in murine experimental models

The concentration of 1.25 mg/mL of BS was selected to evaluate the anti-Candida activity in a murine experimental model, taking into account that this was the most effective dose in reducing Candida adhesion to HeLa cells, by the different mechanisms studied.

Safety assay of BS

In order to assess the safety of BS, mice were inoculated for 14 days for cytological and histological evaluation of the murine vaginal tract. The analysis evidenced no adverse effect of BS (Additional file 1: Fig. S1a, b). The May–Grünwald–Giemsa-stained vaginal smears revealed a vaginal discharge of cornified surface cells with pyknotic nucleus or flakes and keratinized cell groups in both control and BS-treated mice (Additional file 1: Fig. S1a). Also, the characteristics of the vaginal epithelium and lamina propria were similar in BS-treated and control groups at days 7 and 14 post-BS inoculation (Additional file 1: Fig. S1b).

Effect of BS on cultivable murine vaginal microbiota

The inoculation of BS did not significantly affect the number of viable lactic acid bacteria, enterococci, staphylococci, and enterobacteria, although a decrease in the number of viable enterobacteria was observed at day 14 post-BS inoculation compared to control mice (P > 0.05) (Additional file 1: Fig. S1c).

Anti-Candida activity of BS in mice experimental model

The effect of administration of BS by preventive, simultaneous and preventive–simultaneous protocols against challenge with C. albicans 2 was determined. The C. albicans 2 strain was employed in these assays, since it was characterised by the lowest adhesion to HeLa cells in the presence of BS.

Candida viable cells were enumerated in mice vaginal samples obtained from the different BS protocols against C. albicans 2 challenge, but a significant inhibitory effect was not observed. However, the lowest C. albicans 2 viable cell counts were observed in the preventive and preventive-simultaneous protocols at all the sampling days compared to controls (Fig. 7a).

Fig. 7

Anti-Candida activity of biosurfactant (BS) from L. crispatus BC1 in a murine experimental model. aC. albicans 2 (C.a.) viable cells and b leukocytes in vaginal samples of mice receiving preventive (P), preventive–simultaneous (P–S) or simultaneous (S) intravaginally ( administration of BS against challenge with C.a. C and BS correspond to mice inoculated only with C.a. and BS, respectively. Data are plotted as average values of C.a. viable cell or leukocyte numbers ± standard error. Statistically significant differences between the values of experimental groups on the same sampling day are indicated by different letters (P < 0.05). c May Grunwald–Giemsa-stained vaginal smears and d Hematoxylin–Eosin-stained vaginal slides of the different experimental group at day 1 of sampling. Influx of leukocytes in the vaginal washing and lumen of C.a.-challenged mice is indicated with black arrows. Results are representative of two independent experiments

The cytological and histological studies of the murine vaginal tract demonstrated that the challenge with C. albicans 2 induced a leukocyte influx at all the sampling days (Fig. 7b–d). Notably, this influx was reduced by BS treatments at all the sampling days, being this reduction significant on day 1 post-C.a. challenge in preventive and preventive-simultaneous protocols (Fig. 7b–d).


The antibacterial, antifungal and antiviral effect of some BS from lactobacilli have previously been reported [8, 15, 25, 39,40,41,42,43]. Also, another interesting application attributed to BS from lactic acid bacteria is their use as anti-adhesive agents to prevent pathogen adhesion to the host epithelium and to solid surfaces as biomedical instruments [42,43,44,45,46,47,48,49]. In this context, some authors showed that the action of BS from lactobacilli against Candida is most likely related to anti-adhesive and anti-biofilm effects rather than to antimicrobial activity [43, 45]. However, the anti-adhesive properties of BS are frequently determined in in vitro models on polystyrene plates, although the use of plates does not mimic the in vivo conditions of epithelial cells [39, 42, 43, 45]. Moreover, the safety of BS must be assessed before its application in humans, and in vitro cytotoxicity assays and experimental animal models are available [43]. In the present work, a new BS was isolated from a vaginal L. crispatus strain, and its anti-adhesive effect against Candida spp. were investigated on human epithelial cells and, for the first time, in a murine experimental model. Also, the chemical characterization of BS was carried out in order to define the structure and/or composition of this biomolecule. The employment of a vaginal-derived BS to prevent or treat Candida infection in the vaginal environment represents the main novelty of this study.

The results of FT-IR analysis demonstrated a non-homogeneous chemical composition and a lipopeptidic nature of the BS isolated from L. crispatus BC1. Moreover, BS possesses surface tension property along with a CMC value corresponding to 2 mg/mL. This result was in agreement with previous reports of BS produced by lactobacilli [16, 35, 49] or synthetic surfactant, such as sodium dodecyl sulphate (SDS) [50]. In addition, a good emulsification property of BS against olive oil, sunflower oil and wheat germ oil was demonstrated. As regard to the CMC and the emulsification property, similar results were also determined in our previous work, where BS isolated from L. gasseri BC9 showed a high surface activity and a CMC value corresponding to 2.5 mg/mL [26].

Even though the biosurfactant was obtained from a Generally Recognized As Safe (GRAS) microorganism, in the present work we evaluated BS cytotoxicity on human epithelial cells and BS turned to be non-cytotoxic at the concentration of 1.25 mg/mL. Higher BS concentrations significantly decreased cell viability, possibly due to a detergent-like effect leading to cell membrane disruption [35, 51, 52]. Similarly, Ferreira et al. [53] evaluated the cytotoxicity of a BS from L. paracasei using a mouse fibroblast cell line and demonstrated that 5 and 10 mg/mL BS showed cell proliferation values of 97% and 64%, respectively, whereas 0.5 mg/mL SDS, a synthetic well known surfactant, showed a strong inhibitory effect. Sharma et al. [35] have also studied the cytotoxicity of BS from L. helveticus on a mouse fibroblast cell line, but the results demonstrated 43.3% cell viability at 0.0625 mg/mL BS, showing similar toxicity when compared with SDS. On the other hand, Chiewpattanaku et al. [24] evaluated the cytotoxicity of a BS produced by Exophiala dermatitidis fungus against tumor cell lines [HeLa and leukemia (U937)] and normal cell lines [African green monkey kidney (Vero) and peripheral blood mononuclear cells (PBMC)]. The authors reported the anti-proliferative activity against HeLa and U937 cell lines [Inhibitory concentration 50 (IC50) 0.029 mg/mL and 0.049.85 mg/mL, respectively] in a dose-dependent manner and no cytotoxicity in normal cells even when high concentrations were used. The results obtained in this work indicate that 1.25 mg/mL BS from L. crispatus BC1 is not cytotoxic to HeLa cells.

The therapy and control of infections produced by Candida species require strategies combining antifungal agents with substances that block the adhesion to host cells or medical device surfaces [54]. Biosurfactants can adsorb to surfaces, forming a film at the interfaces by orienting polar and nonpolar groups according to the surface hydrophilicity/hydrophobicity. The interaction between BS and a substratum surface alters the hydrophobicity, thereby interfering with microbial adhesion and desorption processes [55, 56]. Thus, the application of BS from lactobacilli could disturb Candida adhesion and desorption processes by interfering with hydrophobicity [25, 43]. The inhibition potential of BS from L. crispatus BC1 on Candida adhesion was assayed on cervix epithelial cells (HeLa) since this cell line represents a well-established model to study Lactobacillus/Candida adhesion, and, previously, such anti-Candida activity was demonstrated for L. crispatus BC1 whole cells on the same cellular model [28]. Adhesion assays showed that BS from L. crispatus BC1 was able to decrease the adhesion of all the Candida strains tested. However, differences in the adhesion were evidenced among strains of the same species (C. albicans), and of different species (C. tropicalis, C. krusei and C. glabrata). In this way, BS could induce changes in the cell surface characteristics and modify the interface contributing to the inhibition of the adherence of yeast to the epithelial cells. In addition, the cell surface differences in carbohydrate and protein concentrations between the Candida strains could contribute to the modulation of cell adhesion [57].

When evaluating the mechanisms by which the BS from L. crispatus BC1 interferes with the adhesion of Candida spp. to HeLa cells, the exclusion assay showed to be the most effective. In a similar way, Itapary Dos Santos et al. [43] demonstrated that BS isolated from Lactobacillus reference strains (L. rhamnosus ATCC 9595 and L. acidophilus ATCC 4356) and vaginal (L. paracasei 11 and L. gasseri 1) reduced C. albicans adhesion and disrupted the biofilm formation on polystyrene plates, obtaining better results in pre-incubation assay than in co-incubation experiments. Thus, the results suggest the potential use of BS from L. crispatus BC1 as a pharmaceutical ingredient for the prevention of recurrent VVC, because the long-term azole treatment (producing longer asymptomatic periods between recurrences) does not provide a definitive cure [58, 59].

In order to corroborate the results obtained from in vitro studies and to overcome the limits of the employment of cervical cells, a murine experimental model was employed. In a first step, the inoculation of 7 and 14 doses BS did not produce modification in the murine vaginal cytology and histology and did not significantly affect the number of cultivable bacteria evaluated in vaginal washings. These results suggest that the application of BS (1.25 mg/mL) is safe and does not modify the cultivable vaginal microbiota. Similar to the present work, analytical methods of cultivation and isolation were widely applied in several laboratory animals in order to evaluate their vaginal microbiota [32, 34, 60,61,62]. Taking into account that the cultured-based technique used in the present work does not allow the isolation of uncultured microorganisms, further studies should be carried out by applying molecular methodologies to evaluate the effect of BS from L. crispatus BC1 on different murine vaginal microbial populations.

As member of the normal human microbiota, C. albicans commonly colonizes the vaginal lumen asymptomatically [63]. However, symptomatic infection can result from exuberant mucosal inflammation that is caused primarily by fungal overgrowth in the vagina and subsequent epithelial invasion and production of virulence effectors [64]. The yeast-to-hypha switch under morphogenesis-inducing conditions (e.g., increases in estrogen, elevated vaginal pH, and microbiome disruption) induces an augmented recognition by pattern recognition receptors (PRR) on the epithelial surface, increased hyphal biomass, expression of hypha-associated virulence factors that activates NLRP3 inflammasome signaling, eliciting inflammatory cytokines and chemokines in the vaginal epithelium, resulting in initial migration of polymorphonuclear leukocytes (PMNs) from the lamina propria to the vaginal lumen. The failure to adequately reduce immunopathological triggers results in the continued expression of innate immune effectors by the vaginal epithelium. These initial signals, coupled with the secondary amplification of immune effectors by recruited PMNs, contribute to symptomatic infection and characteristic immunopathology [65]. Peters et al. [66] have demonstrated that the depletion of PMNs with neutralizing antibodies neither reduced fungal load nor mucosal damage levels during infection, suggesting that neutrophils are non-protective under such conditions and that mucosal damage is mediated by the fungus. Thus, it has been suggest that targeting the NLRP3 inflammasome during VVC may be a rational therapeutic option for disease management [64]. When evaluating the preventive, simultaneous and preventive-simultaneous effect of BS against the challenge with C. albicans 2 in the murine experimental model, a significant decrease in Candida colonization was not observed with the different protocols applied. However, a significant reduction in the leukocyte influx induced by the fungus was evidenced with the preventive and preventive–simultaneous administration of BS (Fig. 7a, b). The ability of the BS molecule to interact with mucin could imply an increase of the residence time at the application site and, consequently, a longer contact period with the vaginal mucosa [67]. Thus, the decrease of the leukocyte influx induced by C. albicans 2 strain when preventive and preventive-simultaneous protocols were applied could be explained by the interaction of BS with the mucin secreted by the vaginal epithelium, that could delay the contact of the fungus with the epithelium. Thus, the results suggest that BS preventive application could avoid the mucosal damage mediated by C. albicans during VVC, consequently reducing the high levels of inflammatory cytokines in the genital tract that could cause mucosal vulnerability and increased risk of HIV and sexually transmitted infection (STI) acquisition [68].

In the present work a murine model was employed to evaluate the host–Candida/BS interactions in the vaginal environment. We are aware that there are some differences between physiology and characteristic of humans and our murine model counterpart, such as vaginal pH, native microbiota, type and duration of sexual cycle, and immune repertoire [69]. In general, low amounts or absence of lactobacilli and a neutral pH in murine vagina are reported, unlike the high number of lactobacilli and low pH, which are characteristics of the human vagina [70]. However, given the success of other described vaginal disease mouse models [32, 33, 69, 71,72,73], and our findings thus far, we believe this model has useful applications in studying host–Candida or BS interactions in the vaginal environment. To the best of our knowledge, the effect of BS isolated from vaginal lactobacilli on Candida albicans in a murine experimental model was not reported to date.


In this study, a biosurfactant produced by vaginal L. crispatus BC1 was chemically and biologically characterized. The BS presented a non-homogeneous chemical composition and a lipopeptide nature, a CMC value corresponding to 2 mg/mL, and a good emulsification capability against olive oil, sunflower oil, and wheat germ oil. Moreover, BS reduced the Candida strains’ ability to adhere to human cervical epithelial cells, mainly by exclusion mechanism. Employing a murine experimental model, it was evidenced that the inoculation of BS did not affect the vaginal cytology, histology and vaginal microbiota (cultivable); but reduced the influx the leukocytes induced by the challenge with C. albicans. This study represents the first characterization of BS from vaginal L. crispatus BC1 and its potential to interfere with Candida adhesion and the mucosal inflammation mediated by the fungus during VVC. However, further studies are required to deeply investigate such properties of BS and its potential use in humans.

Availability of data and materials

All data generated or analysed during this study are included in this published article and its additional information files.



Vulvovaginal candidiasis





Man, Rogosa and Sharpe


Fourier transformed infrared spectroscopy


Mass spectrometry


Critical micellar concentration


Emulsification index


Human cervical cells




Dulbecco’s minimal essential medium


Colony forming units


Analysis of variance


Sodium dodecyl sulphate


Candida albicans








Polymorphonuclear leukocytes


  1. 1.

    Rodríguez-Cerdeira C, Gregorio MC, Molares-Vila A, López-Barcenas A, Fabbrocini G, Bardhi B, et al. Biofilms and vulvovaginal candidiasis. Colloids Surf B Biointerfaces. 2019;174:110–25.

    PubMed  Article  CAS  Google Scholar 

  2. 2.

    González-Burgos E, Gómez-Serranillos MP. Natural products for vulvovaginal Candidiasis treatment: evidence from clinical trials. Curr Top Med Chem. 2018;18:1324–32.

    PubMed  Article  CAS  Google Scholar 

  3. 3.

    Nader-Macías MEF, Juárez Tomás MS. Profiles and technological requirements of urogenital probiotics. Adv Drug Deliv Rev. 2015;92:84–104.

    PubMed  Article  CAS  Google Scholar 

  4. 4.

    Witkin S. The vaginal microbiome, vaginal anti-microbial defense mechanisms and the clinical challenge of reducing infection-related preterm birth. BJOG. 2015;122:213–8.

    CAS  PubMed  Article  Google Scholar 

  5. 5.

    Mendling W. Vaginal microbiota. Adv Exp Med Biol. 2016;902:83–93.

    PubMed  Article  Google Scholar 

  6. 6.

    Reid G. Probiotics: definition, scope and mechanisms of action. Best Pr Res Clin Gastroenterol. 2016;30:17–25.

    CAS  Article  Google Scholar 

  7. 7.

    Ñahui Palomino RA, Zicari S, Vanpouille C, Vitali B, Margolis L. Vaginal Lactobacillus inhibits HIV-1 replication in human tissues ex vivo. Front Microbiol. 2017;8:906.

    PubMed  PubMed Central  Article  Google Scholar 

  8. 8.

    Foschi C, Salvo M, Cevenini R, Parolin C, Vitali B, Marangoni A. Vaginal lactobacilli reduce Neisseria gonorrhoeae viability through multiple strategies: an in vitro study. Front Cell Infect Microbiol. 2017;7:502.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  9. 9.

    Parolin C, Frisco G, Foschi C, Giordani B, Salvo M, Vitali B, et al. Lactobacillus crispatus BC5 interferes with Chlamydia trachomatis infectivity through Integrin modulation in cervical cells. Front Microbiol. 2018;9:2630.

    PubMed  PubMed Central  Article  Google Scholar 

  10. 10.

    Reid G. Therapeutic opportunities in the vaginal microbiome. Microbiol Spectr. 2017.

    Article  PubMed  Google Scholar 

  11. 11.

    Vitali B, Abruzzo A, Parolin C, Palomino RAÑ, Dalena F, Bigucci F, et al. Association of Lactobacillus crispatus with fructo-oligosaccharides and ascorbic acid in hydroxypropyl methylcellulose vaginal insert. Carbohydr Polym. 2016;136:1161–9.

    CAS  PubMed  Article  Google Scholar 

  12. 12.

    FAO/WHO. Working group report on drafting guidelines for the evaluation of probiotics in food. London, Ontario, Canada, April 30 and May 1. 2002.

  13. 13.

    Hill C, Guarner F, Reid G, Gibson G, Merenstein D, Pot B, et al. Expert consensus document: the International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11:506–14.

    PubMed  Article  Google Scholar 

  14. 14.

    Shanahan F, Stanton C, Ross P, Hill C. Pharmabiotics: bioactives from mining host-microbe-dietary interactions. Funct Food Rev. 2009;1:20–5.

    Google Scholar 

  15. 15.

    Satpute SK, Kulkarni GR, Banpurkar AG, Banat IM. Biosurfactant/s from Lactobacilli species: properties, challenges and potential biomedical applications. J Basic Microbiol. 2016;56:1–19.

    Article  Google Scholar 

  16. 16.

    Sharma D, Singh B. Functional characterization of biomedical potential of biosurfactant produced by Lactobacillus helveticus. Biotechnol Rep. 2016;11:27–35.

    Article  Google Scholar 

  17. 17.

    Allonsius CN, Van Den Broek MFL, De Boeck I, Kiekens S, Oerlemans EFM, Kiekens F, et al. Interplay between Lactobacillus rhamnosus GG and Candida and the involvement of exopolysaccharides. Microb Biotechnol. 2017;10:1753–63.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  18. 18.

    Sungur T, Aslim B, Karaaslan C, Aktas B. Impact of Exopolysaccharides (EPSs) of Lactobacillus gasseri strains isolated from human vagina on cervical tumor cells (HeLa). Anaerobe. 2017;47:137–44.

    PubMed  Article  Google Scholar 

  19. 19.

    Allonsius CN, Vandenheuvel D, Oerlemans EFM, Petrova MI, Donders GGG, Cos P, et al. Inhibition of Candida albicans morphogenesis by chitinase from Lactobacillus rhamnosus GG. Sci Rep. 2019;9:2900.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  20. 20.

    Van Hamme J, Singh A, Ward O. Physiological aspects. Part 1 in a series of papers devoted to surfactants in microbiology and biotechnology. Biotechnol Adv. 2006;24:604–20.

    PubMed  Article  CAS  Google Scholar 

  21. 21.

    Gudiña E, Rangarajan V, Sen R, Rodrigues L. Potential therapeutic applications of biosurfactants. Trends Pharmacol Sci. 2013;34:667–75.

    PubMed  Article  CAS  Google Scholar 

  22. 22.

    Sambanthamoorthy K, Feng X, Patel R, Patel S, Paranavitana C. Antimicrobial and anti-biofilm potential of biosurfactants isolated from lactobacilli against multi-drug-resistant pathogens. BMC Microbiol. 2014;14:197.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  23. 23.

    Marchant R, Banat I. Microbial biosurfactants: challenges and opportunities for future exploitation. Trends Biotechnol. 2012;30:558–65.

    CAS  PubMed  Article  Google Scholar 

  24. 24.

    Chiewpattanakul P, Phonnok S, Durand A, Marie E, Thanomsub BW. Bioproduction and anticancer activity of biosurfactant produced by the dematiaceous fungus Exophiala dermatitidis SK80. J Microbiol Biotechnol. 2010;20:1664–71.

    CAS  PubMed  Google Scholar 

  25. 25.

    Morais IMC, Cordeiro AL, Teixeira GS, Domingues VS, Nardi RMD, Monteiro AS, et al. Biological and physicochemical properties of biosurfactants produced by Lactobacillus jensenii P6A and Lactobacillus gasseri P65. Microb Cell Fact. 2017;16:155.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  26. 26.

    Abruzzo A, Giordani B, Parolin C, Vitali B, Protti M, Mercolini L, et al. Novel mixed vesicles containing lactobacilli biosurfactant for vaginal delivery of an anti-Candida agent. Eur J Pharm Sci. 2018;112:95–101.

    CAS  PubMed  Article  Google Scholar 

  27. 27.

    Giordani B, Costantini PE, Fedi S, Cappelletti M, Abruzzo A, Parolin C, et al. Liposomes containing biosurfactants isolated from Lactobacillus gasseri exert antibiofilm activity against methicillin resistant Staphylococcus aureus strains. Eur J Pharm Biopharm. 2019;139:246–52.

    CAS  PubMed  Article  Google Scholar 

  28. 28.

    Parolin C, Marangoni A, Laghi L, Foschi C, Ñahui Palomino RA, Calonghi N, et al. Isolation of vaginal lactobacilli and characterization of anti-Candida activity. PLoS ONE. 2015;10:e0131220.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  29. 29.

    Cooper DG, Goldenberg BG. Surface-active agents from two Bacillus species. Appl Environ Microbiol. 1987;53:224–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  30. 30.

    Cerchiara T, Abruzzo A, Di Cagno M, Bigucci F, Bauer-Brandl A, Parolin C, et al. Chitosan based micro- and nanoparticles for colon-targeted delivery of vancomycin prepared by alternative processing methods. Eur J Pharm Biopharm. 2015;92:112–9.

    CAS  PubMed  Article  Google Scholar 

  31. 31.

    Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55–63.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  32. 32.

    De Gregorio PR, Juares Tomás MS, Leccese Terraf MC, Nader-Macías MEF. Preventive effect of Lactobacillus reuteri CRL1324 on Group B Streptococcus vaginal colonization in an experimental mouse model. J Appl Microbiol. 2015;118:1034–47.

    PubMed  Article  CAS  Google Scholar 

  33. 33.

    De Gregorio P, Silva J, Marchesi A, Nader-Macías M. Anti-Candida activity of beneficial vaginal lactobacilli in in vitro assays and in a murine experimental model. FEMS Yeast Res. 2019;19:foz008.

    PubMed  Article  CAS  Google Scholar 

  34. 34.

    De Gregorio PR, Salva S, Tomás MSJ, Nader-Macías MEF. Effects of exogenous sex hormones on mouse estrous cycle, vaginal microbiota and immune cells. Scand J Lab Anim Sci. 2018;44:1–14.

    Google Scholar 

  35. 35.

    Sharma D, Saharan BS, Chauhan N, Bansal A, Procha S. Production and structural characterization of Lactobacillus helveticus derived biosurfactant. Sci World J. 2014;2014:493548.

    Google Scholar 

  36. 36.

    Elazzazy AM, Abdelmoneim TS, Almaghrabi OA. Isolation and characterization of biosurfactant production under extreme environmental conditions by alkali-halo-thermophilic bacteria from Saudi Arabia. Saudi J Biol Sci. 2015;22:466–75.

    CAS  PubMed  Article  Google Scholar 

  37. 37.

    Tiwary M, Dubey AK. Characterization of biosurfactant produced by a novel strain of Pseudomonas aeruginosa, isolate ADMT1. J Surfactants Deterg. 2018;21:113–25.

    CAS  Article  Google Scholar 

  38. 38.

    Rufino RD, de Luna JM, de Campos Takaki GM, Sarubbo LA. Characterization and properties of the biosurfactant produced by Candida lipolytica UCP 0988. Electron J Biotechnol. 2014;17:34–8.

    Article  CAS  Google Scholar 

  39. 39.

    Gudiña EJ, Fernandes EC, Teixeira JA, Rodrigues LR. Antimicrobial and anti-adhesive activities of cell-bound biosurfactant from Lactobacillus agilis CCUG31450. RSC Adv. 2015;5:90960–8.

    Article  Google Scholar 

  40. 40.

    Velraeds MMC, Van Der Mei HC, Reid G, Busscher HJ. Physicochemical and biochemical characterization of biosurfactants released by Lactobacillus strains. Colloids Surfaces B Biointerfaces. 1996;8:51–61.

    CAS  Article  Google Scholar 

  41. 41.

    Velraeds MMC, Van der Mei HC, Reid G, Busscher HJ. Inhibition of initial adhesion of uropathogenic Enterococcus faecalis to solid substrata by an adsorbed biosurfactant layer from Lactobacillus acidophilus. Urology. 1997;49:790–4.

    CAS  PubMed  Article  Google Scholar 

  42. 42.

    Gudiña EJ, Rocha V, Teixeira JA, Rodrigues LR. Antimicrobial and antiadhesive properties of a biosurfactant isolated from Lactobacillus paracasei ssp. paracasei A20. Lett Appl Microbiol. 2010;50:419–24.

    PubMed  Article  CAS  Google Scholar 

  43. 43.

    Itapary dos Santos C, Ramos França Y, Duarte Lima Campos C, Quaresma Bomfim MR, Oliveira Melo B, Assunção Holanda R, et al. Antifungal and antivirulence activity of vaginal Lactobacillus spp. products against Candida vaginal isolates. Pathogens. 2019;8:150.

    PubMed Central  Article  CAS  Google Scholar 

  44. 44.

    Velraeds MMC, Van Belt-Gritter B, De Busscher HJ, Reid G, Van Der Mei HC. Inhibition of uropathogenic biofilm growth on silicone rubber in human urine by lactobacilli—a teleologic approach. World J Urol. 2000;18:422–6.

    CAS  PubMed  Article  Google Scholar 

  45. 45.

    Fracchia L, Cavallo M, Allegrone G, Martinotti MG. A Lactobacillus-derived biosurfactant inhibits biofilm formation of human pathogenic Candida albicans biofilm producers. Appl Microbiol Biotechnol. 2010;2:827–37.

    Google Scholar 

  46. 46.

    Rodrigues L, Van Der Mei HC, Teixeira J, Oliveira R. Influence of biosurfactants from probiotic bacteria on formation of biofilms on voice prostheses. Appl Environ Microbiol. 2004;70:4408–10.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  47. 47.

    Busscher HJ, Van Hoogmoed CG, Geertsema-Doornbusch GI, Van Der Kuijl-Booij M, Van Der Mei HC. Streptococcus thermophilus and its biosurfactants inhibit adhesion by Candida spp. on silicone rubber. Appl Environ Microbiol. 1997;63:3810–7.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  48. 48.

    Van Der Mei HC, Free RH, Elving GJ, Van Weissenbruch R, Albers FWJ, Busscher HJ. Effect of probiotic bacteria on prevalence of yeasts in oropharyngeal biofilms on silicone rubber voice prostheses in vitro. J Med Microbiol. 2000;49:713–8.

    Article  Google Scholar 

  49. 49.

    Thavasi R, Jayalakshmi S, Banat IM. Effect of biosurfactant and fertilizer on biodegradation of crude oil by marine isolates of Bacillus megaterium, Corynebacterium kutscheri and Pseudomonas aeruginosa. Bioresour Technol. 2011;102:772–8.

    CAS  PubMed  Article  Google Scholar 

  50. 50.

    Mulligan CNGBP. Types, production and applications of biosurfactants. Indian Natl Sci Acad. 2004;70:31–55.

    CAS  Google Scholar 

  51. 51.

    de Kruijff B, Gerritsen WJ, Oerlemans A, Demel RA, van Deenen LL. Polyene antibiotic-sterol interactions in membranes of Acholeplasma laidlawii cells and lecithin liposomes. I. Specificity of the membrane permeability changes induced by the polyene antibiotics. Biochim Biophys Acta. 1974;339:30–43.

    PubMed  Article  Google Scholar 

  52. 52.

    Akiyode O, George D, Getti G, Boateng J. Systematic comparison of the functional physico-chemical characteristics and biocidal activity of microbial derived biosurfactants on blood-derived and breast cancer cells. J Colloid Interface Sci. 2016;479:221–33.

    CAS  PubMed  Article  Google Scholar 

  53. 53.

    Ferreira A, Vecino X, Ferreira D, Cruz JM, Moldes AB, Rodrigues LR. Novel cosmetic formulations containing a biosurfactant from Lactobacillus paracasei. Colloids Surf B Biointerfaces. 2017;155:522–9.

    CAS  PubMed  Article  Google Scholar 

  54. 54.

    Douglas LJ. Candida biofilms and their role in infection. Trends Microbiol. 2003;11:30–6.

    CAS  PubMed  Article  Google Scholar 

  55. 55.

    Neu TR. Significance of bacterial surface-active compounds in interaction of bacteria with interfaces. Microbiol Rev. 1996;60:151–66.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  56. 56.

    Rodrigues LR, Teixeira JA, van der Mei HC, Oliveira R. Physicochemical and functional characterization of a biosurfactant produced by Lactococcus lactis 53. Colloids Surf B Biointerfaces. 2006;49:79–86.

    CAS  PubMed  Article  Google Scholar 

  57. 57.

    Ferreira GF, dos Santos Pinto BL, Souza EB, Viana JL, Zagmignan A, dos Santos JRA, et al. Biophysical effects of a polymeric biosurfactant in Candida krusei and Candida albicans cells. Mycopathologia. 2016;181:799–806.

    CAS  PubMed  Article  Google Scholar 

  58. 58.

    Sobel J. Recurrent vulvovaginal candidiasis. Am J Obs Gynecol. 2016;214:15–21.

    Article  Google Scholar 

  59. 59.

    Foxman B, Muraglia R, Dietz J, Sobel J, Wagner J. Prevalence of recurrent vulvovaginal candidiasis in European countries and the United States: results from an internet panel survey. J Low Genit Tract Dis. 2013;17:340–5.

    PubMed  Article  Google Scholar 

  60. 60.

    Meysick KC, Garber GE. Interactions between Trichomonas vaginalis and vaginal flora in a mouse model. J Parasitol. 1992;78:157–60.

    CAS  PubMed  Article  Google Scholar 

  61. 61.

    Noguchi K, Tsukumi K, Urano T. Qualitative and quantitative differences in normal vaginal flora of conventionally reared mice, rats, hamsters, rabbits, and dogs. Comp Med. 2003;53:404–12.

    CAS  PubMed  Google Scholar 

  62. 62.

    Voronkova OS, Sirokvasha EA, Vinnikov AI. Experimental vaginal dysbiosis on the model of white laboratory mice. Mikrobiol Z. 2008;70:47–58.

    CAS  PubMed  Google Scholar 

  63. 63.

    Achkar JM, Fries BC. Candida infections of the genitourinary tract. Clin Microbiol Rev. 2010;23:253–73.

    PubMed  PubMed Central  Article  Google Scholar 

  64. 64.

    Willems HME, Ahmed SS, Liu J, Xu Z, Peters BM. Vulvovaginal Candidiasis: a current understanding and burning questions. J Fungi. 2020;6:E27.

    Article  Google Scholar 

  65. 65.

    Peters BM, Yano J, Noverr MC, Fidel PL Jr. Candida Vaginitis: when opportunism knocks, the host responds. PLoS Pathog. 2014;10:e1003965.

    PubMed  PubMed Central  Article  Google Scholar 

  66. 66.

    Peters BM, Palmer GE, Nash AK, Lilly EA, Fidel PL, Noverra MC. Fungal morphogenetic pathways are required for the hallmark inflammatory response during Candida albicans vaginitis. Infect Immun. 2014;82:532–43.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  67. 67.

    de Araújo PR, Calixto GMF, da Silva IC, de Paula Zago LH, Oshiro Junior JA, Pavan FR, et al. Mucoadhesive in situ gelling liquid crystalline precursor system to improve the vaginal administration of drugs. AAPS PharmSciTech. 2019;20(6):225.

    PubMed  Article  CAS  Google Scholar 

  68. 68.

    Alcaide ML, Rodriguez VJ, Brown MR, Pallikkuth S, Arheart K, Martinez O, et al. High evels of inflammatory cytokines in the reproductive tract of women with BV and engaging in intravaginal douching: a cross-sectional study of participants in the women interagency HIV study. AIDS Res Hum Retrovir. 2017;33:309–17.

    CAS  PubMed  Article  Google Scholar 

  69. 69.

    Patras KA, Wang NY, Fletcher EM, Cavaco CK, Jimenez A, Garg M, et al. Group B Streptococcus CovR regulation modulates host immune signalling pathways to promote vaginal colonization. Cell Microbiol. 2013;15:1154–67.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  70. 70.

    Muench DF, Kuch DJ, Wu H, Begum AA, Veit SJ, Pelletier M, et al. Hydrogen peroxide-producing lactobacilli inhibit gonococci in vitro but not during experimental genital tract infection. J Infect Dis. 2009;199:1369–78.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  71. 71.

    Joo HM, Kim KA, Myoung KS, Ahn YT, Lee JH, Huh CS, et al. Lactobacillus helveticus HY7801 ameliorates vulvovaginal candidiasis in mice by inhibiting fungal growth and NF-κB activation. Int Immunopharmacol. 2012;14:39–46.

    CAS  PubMed  Article  Google Scholar 

  72. 72.

    Joo HM, Hyun YJ, Myoung KS, Ahn YT, Lee JH, Huh CS, et al. Lactobacillus johnsonii HY7042 ameliorates Gardnerella vaginalis-induced vaginosis by killing Gardnerella vaginalis and inhibiting NF-κB activation. Int Immunopharmacol. 2011;11:1758–65.

    CAS  PubMed  Article  Google Scholar 

  73. 73.

    De Gregorio PR, Juárez Tomás MS, Nader-Macías MEF. Immunomodulation of Lactobacillus reuteri CRL1324 on Group B Streptococcus vaginal colonization in a murine experimental model. Am J Reprod Immunol. 2016;75:23–35.

    PubMed  Article  CAS  Google Scholar 

Download references


We are grateful for the helpful cooperation of Antonella Marchesi and Eduardo Villamil in in vivo assays.


This work was supported by Italian Ministry of Foreign Affairs and International Cooperation scholarships (MAECI), Agencia Nacional de Promoción Científica y Tecnológica (ANPCyT) [PICT 2017-4324 and PICT 2018-00670].

Author information




PRDG: design of the work, data acquisition and interpretation of in vitro and in vivo assays, original draft of the manuscript. CP: conception of the work, data analysis and interpretation of in vitro assays, substantial revision of the manuscript. AA: data acquisition and interpretation of technological assays. BL: conception of the work, supervision of technological assays. MP: data acquisition and interpretation of MS analysis. LM: supervision of MS analysis. JAS: data acquisition and interpretation of in vivo assays. BG: data acquisition and interpretation of technological assays. AM: supply of Candida strains. MEFN: financial funding, supervision of in vivo assays. BV: financial funding, conception of the work, substantial revision of the manuscript. All authors contribute to manuscript generation. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Priscilla Romina De Gregorio or Carola Parolin.

Ethics declarations

Ethics approval and consent to participate

The Institutional Laboratory Animal Care and Use Committee of CERELA approved the experimental protocol applied in this work (CRL-BIOT-FB-2019/1A).

The Ethics Committee of the University of Bologna approved the isolation procedure of L. crispatus BC1 (Protocol 52/2014/U/Tess).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Additional file 1: Fig. S1. Effect of biosurfactant (BS) from L. crispatus BC1 on murine vaginal cytology, histology and microbiota. Photographs of (a) May Grunwald–Giemsa-stained vaginal smears and (b) Hematoxylin–Eosin-stained vaginal slides from BALB/c mice intravaginally ( inoculated with 20 µL of saline (control mice) or 20 µL of biosurfactant from L. crispatus BC1 (BS, 1.25 mg/mL) (BS-treated mice), for 7 or 14 days. Results are representative of two independent experiments. (c) Viable cells of lactic acid bacteria, enterococci, staphylococci and enterobacteria from murine vaginal washings (v.w.) of the two experimental groups (BS and control) at days 0, 7 and 14 post-BS inoculation. The data are plotted as the mean values of viable cell numbers (Log CFU/mL) ± standard error.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

De Gregorio, P.R., Parolin, C., Abruzzo, A. et al. Biosurfactant from vaginal Lactobacillus crispatus BC1 as a promising agent to interfere with Candida adhesion. Microb Cell Fact 19, 133 (2020).

Download citation


  • Vagina
  • Lactobacillus crispatus
  • Candida spp.
  • Biosurfactant
  • HeLa cells
  • Murine model
  • Vulvovaginal candidiasis
  • Anti-Candida activity